D.Western Therapeutics Institute,Inc.is a biotechnology company that focuses on development of innovative new drags to serve patients worldwide.

Product Pipeline

Product Pipeline

As of Feb 2019

DWTI Product Pipeline


※ K-134 has been targeted arteriosclerosis obliterans as indication, developed and completed phase 2 by Kowa Company, Ltd.. Meanwhile, Kowa is now considering another target disease.

pdficon_large394KB(Enlarge the above diagram)

GLANATEC® ophthalmic solution 0.4% ▶Learn more

WP-1303(H-1129) ▶Learn more

H-1337 ▶Learn more

K-134 ▶Learn more

DW-1002 ▶Learn more

Japan Innovative Therapeutics, Inc. Product Pipeline


pdficon_large108KB(Enlarge the above diagram)

D.Western Therapeutics Institute, Inc.
1-18-11, Nishiki, Naka-ku,
Nagoyashi, Aichi 460-0003 Japan
TEL 81+52-218-8785
Copyright © D.Western Therapeutics Institute, Inc. All Rights Reserved.